Browse our anti-CD19 (CD19) Antibodies

Human CD19 Molecule (CD19) interaction partners

1. CD3(+)TCRalphabeta(+) and CD19(+) cell-depleted haploidentical or mMUD HSCT is a practical and viable alternative for children with a range of PIDs.

2. CD19ex2vs fail to bind to the key tetraspanin CD81.

3. Multicolor flow cytometry (FCM) effective for minimal residual disease (MRD) detection following CD19-targeted CAR-T cell therapy on B-lymphoblastic leukemia (B-ALL) patients.

4. Patients receiving anti-CD19 therapies demonstrate an increased proportion of CD19-negative progenitors.

5. Here we have developed a novel CAR construct capable of inducing cytokine signaling after antigen stimulation. This new-generation CD19 CAR encodes a truncated cytoplasmic domain from the interleukin (IL)-2 receptor beta-chain (IL-2Rbeta) and a STAT3-binding tyrosine-X-X-glutamine (YXXQ) motif, together with the TCR signaling (CD3z) and co-stimulatory (CD28) domains (hereafter referred to as 28-DeltaIL2RB-z(YXXQ)).

6. CD19 and CD81 were significantly reduced and correlated with disease activity in Systemic Lupus Erythematosus

7. In patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia who failed treatment with blinatumomab, had a minimal change in CD19 expression. At the time of failure, among 61 patients evaluated for immunophenotype, 56 (92%) had CD19-positive blasts; only five (8%) had ALL recurrence with CD19-negative disease. Two patients progressed with lower CD19 expression.

8. a novel mechanism for Dock8 regulation of BCR signaling by regulating cd19 transcription

9. These data suggest that Igbeta and CD19 are part of an alternative B-cell signaling module that use continuous ITAM/PI3K signaling to promote the survival of B lymphoma and normal B cells.

10. Development of Inducible CD19-CAR T cells with a tet-on system for controlled activity and enhanced clinical safety has been reported.

11. diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.

12. CD4(+) and CD19(+) peripheral lymphocytes of early stage AD patients exhibit mitochondrial depletion, as seen both at the level of DNA and protein

13. The impairment of Bregs and CD19+/BTLA+ cells could play an important pathogenic role in multiple sclerosis (MS).

14. Inhibition of Akt signaling during ex vivo priming and expansion gives rise to CD19CAR T cell populations that display comparatively higher antitumor activity

15. CD19-specific triplebody SPM-1 mediated potent lysis of cancer-derived B cell lines and primary cells from patients with various B-lymphoid malignancies.

16. The increase in CD19+CD24+CD27+ Bregs was closely associated with fasting insulin secretion.

17. The preclinical activity, safety and PK profile support clinical investigation of MGD011 (MGD011 is a CD19 x CD3 DART bispecific protein )as a therapeutic candidate for the treatment of B-cell malignancies

18. this study shows that CD19 isoforms enable resistance to adoptive cellular immunotherapy

19. Anti-CD19-chimeric antigen receptors T cells synergistically exerted collaborative cytotoxicity against primary double-hit lymphoma cells with anti-CD38-chimeric antigen receptors T cells.

20. Two infants with relapsed, refractory B-cell acute lymphoblastic leukemia went into complete remission after being treated with CD19-targeting CAR T cells derived from an unmatched donor

Mouse (Murine) CD19 Molecule (CD19) interaction partners

1. The results suggest that CD19 controls the differentiation of marginal zone precursors to marginal zone B cells by regulating ADAM28-mediated Notch2 cleavage.

2. This study demonstrates that antiviral protective antibody-secreting cells (ASC) in the central nervous system are dependent on CD19 activation and peripheral Germinal Center formation, while accumulation of early-recruited IgD(+) B cells is CD19 independent.

3. this study shows that mitochondrial reactive oxygen species suppress humoral immune responses through reduction of CD19 expression and resultant B cell receptor signaling in B cells

4. autoimmunity induced by excessive BAFF production requires B1b B cells and CD19 signaling.

5. WIPF1 deficiency impaired CD19 co-receptor activation and subsequent PI3 kinase signaling, by distorting the actin and tetraspanin networks that lead to altered CD19 cell surface dynamics.

6. Syk-deficient B cells require BAFF receptor and CD19/PI3K signaling for their long-term survival.

7. The selection of mature B cells is critically dependent on the expression level of the co-receptor CD19.

8. This inhibitory function of FcgammaRIIB in impairing the spatial-temporal colocalization of BCR and CD19 microclusters in the B cell immunological synapse may help explain the hyper-reactive features of systemic lupus erythematosus

9. These results show that the ability of CD19-CAR T-cells to home in on tumor lesions is pivotal for their anti-tumor effects in our xenograft models, and therefore may enhance the efficacy of adoptive T-cell therapy for refractory B-cell lymphoma.

10. Data show that effective B cell receptor (BCR) signaling requires collaboration with the coreceptor CD19 organized by the CD81-tetraspanin network.

11. results indicate that the CD19/CD81 complex interacts with CD38 but this interaction is not required to induce proliferation in mouse B lymphocytes

12. CD19positive CD45R(lo)positive lymphocytes of embryonic origin are present in Peyer's patches and in the spleen throughout the life span of wild-type mice, beginning at postnatal day 7.

13. We report that regulatory dendritic cells can induce splenic B cells to differentiate into a distinct subtype of IL-10-producing regulatory B cells with unique phenotype CD19(hi)FcgammaIIb(hi).

14. CD19 is a major BCR-independent regulator of MYC-driven neoplastic growth in B cell neoplasms.

15. Data from transgenic/knockout mice indicate that CD19 is not required for generation of marginal zone B-cells under influence of Notch2 signaling; data confirm that in absence of CD19, all B cells shift to marginal zone B-cell compartment.

16. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes CD19 can eradicate lymphoma and normal B cells.

17. CD19 expression has both protective and disease promoting roles in lupus pathogenesis in New Zealand black (NZB) and in New Zealand white F1 hybrid (NZB/W) mice deficient for CD19 (CD19-/-).

18. BCR engagement induced differential Tyr phosphorylation. Y(513) phophorylation occurred 1st; Y(482) phosphorylation was delayed & transient. This affected CD19-mediated downstream pathways. Phosphorylation differed with the plasma membrane location.

19. Ca(2+) down-regulates SLC and CD19 gene expression upon pre-BCR activation through inhibition of E2A by Ca(2+)/calmodulin.

20. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse

Cow (Bovine) CD19 Molecule (CD19) interaction partners

1. DNA sequence analysis of the coding sequence of CD19, the CR2 co-signaling molecule.